Valneva Reports P-III (VLA2001-301) Cov-Compare Study Results of VLA2001 (COVID-19 Vaccine) for COVID-19
Shots:
- The P-III (VLA2001-301) Cov-Compare study evaluates VLA2001 vs ChAdOx1-S in 4012 patients with COVID-19. Following the administration of the booster dose, patients will be followed for ~6mos.
- The results showed persistent immunogenicity at ~2mos.; neutralizing Ab titers were non-inferior to ChAdOx1-S & seroconversion rates remained constant at Day 71 (≥92%). The analysis of T-cell responses on Day 208 revealed that VLA2001 had induced broad Ag-specific IFN-gamma-producing T-cells reactive against S, N & M-proteins
- The heterologous booster results for VLA2001 boosted immunity to higher neutralizing Abs titers in patients primed with ChAdOx1-S. The tolerability profile of a booster dose was similar to the favorable profile after 1st & the 2nd vaccination
Ref: Globe Newswire | Image: Valneva
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
